Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft versus Host Disease

Humanigen, Inc. announced it plans to support a Phase II/III study to evaluate lenzilumab for the early treatment of acute graft versus host disease following allogeneic hematopoietic stem cell transplantation in collaboration with IMPACT.